MARSHBANKS TRACY 4
4 · ANI PHARMACEUTICALS INC · Filed Mar 12, 2018
Insider Transaction Report
Form 4
MARSHBANKS TRACY
Director
Transactions
- Sale
Common Stock
2018-03-09$63.01/sh−36,561$2,303,709→ 497,982 total(indirect: See Footnote) - Sale
Common Stock
2018-03-08$63.08/sh−15,391$970,864→ 534,543 total(indirect: See Footnote) - Sale
Common Stock
2018-03-12$63.03/sh−12,269$773,315→ 485,713 total(indirect: See Footnote)
Footnotes (4)
- [F1]This transaction was executed in multiple trades at prices ranging from $63.00 to $63.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $63.00 to $63.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $63.00 to $63.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1)